NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Hain Celestial Group, Inc. (NASDAQ:HAIN), Allegheny Technologies Incorporated (NYSE:ATI), The Hanover Insurance Group, Inc. (NYSE:THG), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), and Preformed Line Products Company (NASDAQ:PLPC), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

HAIN DOWNLOAD: http://Fundamental-Markets.com/register/?so=HAIN
ATI DOWNLOAD: http://Fundamental-Markets.com/register/?so=ATI
THG DOWNLOAD: http://Fundamental-Markets.com/register/?so=THG
ZBH DOWNLOAD: http://Fundamental-Markets.com/register/?so=ZBH
CRBP DOWNLOAD: http://Fundamental-Markets.com/register/?so=CRBP
PLPC DOWNLOAD: http://Fundamental-Markets.com/register/?so=PLPC

The new research reports from Fundamental Markets, available for free download at the links above, examine The Hain Celestial Group, Inc. (NASDAQ:HAIN), Allegheny Technologies Incorporated (NYSE:ATI), The Hanover Insurance Group, Inc. (NYSE:THG), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), and Preformed Line Products Company (NASDAQ:PLPC) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

For the three months ended December 31st, 2018 vs December 31st, 2017, The Hain Celestial Group reported revenue of $584.16MM vs $616.23MM (down 5.21%) and analysts estimated basic earnings per share -$0.64 vs $0.45. For the twelve months ended June 30th, 2018 vs June 30th, 2017, The Hain Celestial Group reported revenue of $2,457.77MM vs $2,343.51MM (up 4.88%) and analysts estimated basic earnings per share $0.09 vs $0.65 (down 86.15%). Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.37. The estimated EPS forecast for the next fiscal year is $0.82 and is expected to report on August 27th, 2019.

For the three months ended December 31st, 2018 vs December 31st, 2017, Allegheny Technologies reported revenue of $1,037.90MM vs $909.90MM (up 14.07%) and analysts estimated basic earnings per share $0.34 vs $0.04 (up 750.00%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Allegheny Technologies reported revenue of $4,046.60MM vs $3,525.10MM (up 14.79%) and analysts estimated basic earnings per share $1.78 vs -$0.83. Analysts expect earnings to be released on April 23rd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.32. The estimated EPS forecast for the next fiscal year is $2.58 and is expected to report on January 28th, 2020.

For the three months ended December 31st, 2018 vs December 31st, 2017, The Hanover Insurance Group reported revenue of $634.00MM vs $655.00MM (down 3.21%) and analysts estimated basic earnings per share $2.92 vs $1.21 (up 141.32%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, The Hanover Insurance Group reported revenue of $4,494.30MM vs $4,267.90MM (up 5.30%) and analysts estimated basic earnings per share $9.21 vs $4.38 (up 110.27%). Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $1.95. The estimated EPS forecast for the next fiscal year is $8.90 and is expected to report on January 29th, 2020.

For the three months ended December 31st, 2018 vs December 31st, 2017, Zimmer Biomet reported revenue of $2,071.00MM vs $2,068.30MM (up 0.13%) and basic earnings per share -$4.43 vs $6.09. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Zimmer Biomet reported revenue of $7,932.90MM vs $7,803.30MM (up 1.66%) and analysts estimated basic earnings per share -$1.86 vs $8.98. Analysts expect earnings to be released on April 26th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.91. The estimated EPS forecast for the next fiscal year is $8.35 and is expected to report on February 7th, 2020.

For the three months ended December 31st, 2018 vs December 31st, 2017, Corbus Pharmaceuticals reported revenue of $1.93MM vs $0.00MM and analysts estimated basic earnings per share -$0.30 vs -$0.20. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Corbus Pharmaceuticals reported revenue of $4.82MM vs $2.44MM (up 97.62%) and analysts estimated basic earnings per share -$0.98 vs -$0.65. Analysts expect earnings to be released on May 9th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.21. The estimated EPS forecast for the next fiscal year is -$1.23 and is expected to report on March 10th, 2020.

For the three months ended December 31st, 2018 vs December 31st, 2017, Preformed Line Products reported revenue of $105.41MM vs $96.89MM (up 8.79%) and analysts estimated basic earnings per share $1.04 vs $0.14 (up 642.86%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Preformed Line Products reported revenue of $420.88MM vs $378.21MM (up 11.28%) and analysts estimated basic earnings per share $5.28 vs $2.48 (up 112.90%). Analysts expect earnings to be released on May 3rd, 2019. The report will be for the fiscal period ending March 31st, 2019.

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.